Xiaoyu Fan
Shushu Guo
Wanfang Li1,3
Jiuming He
Hongtao Jin- 1New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- 2School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
- 3Beijing Union-Genius Pharmaceutical Technology Development Co. Ltd., Beijing, China
- 4State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- 5Beijing Key Laboratory of Key Technologies for Preclinical Research and Development of Innovative Drugs in Pharmacokinetics and Pharmacodynamics, Beijing, China
Cancer remains a major global health challenge, and although immunotherapy has achieved remarkable breakthroughs, its efficacy is often limited by tumor-induced immunosuppression within the tumor microenvironment (TME). Emerging evidence indicates that metabolic reprogramming plays a pivotal role in shaping the TME and regulating antitumor immune responses. Targeting tumor and immune cell metabolism has therefore become a promising strategy to enhance the effectiveness of cancer immunotherapy. This review first summarizes the metabolic reprogramming that occurs within the TME, including alterations in glucose, lipid, and amino acid metabolism in tumor cells, as well as the metabolic adaptation of immune cells. We then highlight recent advances in natural products that modulate key metabolic pathways and their potential to reshape the immunosuppressive TME. Special emphasis is placed on natural compounds that not only inhibit tumor cell metabolism but also restore the metabolic fitness of immune cells, thereby improving antitumor immunity. In addition, advances in delivery strategies, including nanocarrier-based and stimuli-responsive systems, are reviewed for their roles in improving the bioavailability, stability, and tumor targeting of natural metabolism-regulating agents. Finally, we discuss the current status and challenges of translating natural metabolism-regulating agents into clinical applications, including issues of dose optimization, safety evaluation, and patient selection. Despite these hurdles, precision targeting of metabolic pathways, interdisciplinary collaboration, and the discovery of novel compounds—particularly immune-sensitizing agents derived from traditional medicine—are expected to accelerate progress. Collectively, natural products represent promising adjuvant strategies for cancer immunotherapy, with great potential to overcome current therapeutic limitations and improve clinical outcomes.
1 Introduction
For decades, cancer has remained one of the most significant threats to global public health, with incidence and mortality rates continuing to rise worldwide. Despite advancements in early detection and treatment modalities, cancer imposes a substantial burden on healthcare systems and severely impacts patient quality of life (1). Immunotherapy has emerged as a transformative approach in cancer treatment, offering unprecedented clinical benefits in various malignancies. Strategies such as immune checkpoint blockade, adoptive cell transfer, and cancer vaccines have demonstrated durable responses and long-term survival in subsets of patients (2, 3). However, the efficacy of immunotherapy remains limited by several challenges, including tumor immune evasion (4), an immunosuppressive tumor microenvironment (5), and the low immunogenicity of certain cancer types (6). These limitations underscore the urgent need for novel strategies to enhance the effectiveness of immunotherapy and broaden its clinical applicability.
Targeting cancer metabolic abnormalities has been recognized as a promising strategy to remodel the tumor microenvironment and enhance antitumor immune response (7). Tumor cells undergo profound metabolic reprogramming to support their rapid proliferation, survival, and immune evasion. These metabolic alterations, including increased glucose uptake coupled with abundant lactate secretion, as well as alterations in the tricarboxylic acid cycle (TCA cycle) - has a major impact on the immunological tumor microenvironment (TME) (8). Modulating these aberrant metabolic pathways can disrupt the tumor’s protective microenvironment and restore antitumor immunity (8). Current studies have demonstrated that metabolic interventions can increase immune cell infiltration, enhancing antitumor T cells, suppressive myeloid cells and synergize with immune checkpoint blockade therapies (9, 10). Therefore, targeting tumor metabolism may offer the potential to overcome the current limitations of immunotherapy and expand its clinical efficacy in a wider range of malignancies.
Understanding the metabolic alterations in tumor cells has led to the exploration of targeting these pathways as a therapeutic strategy. However, translating these insights into effective clinical therapies has proven challenging. Although Otto Warburg’s theory of aerobic glycolysis laid the foundation for tumor metabolism research, this metabolic pathway has not been successfully exploited in the clinic, largely due to the adverse side effects and limited efficacy of 2-deoxyglucose, which inhibits glycolysis. Farber’s pioneering use of antifolate drugs established cancer chemotherapy, and another folate antagonist, methotrexate, remains a key component of childhood acute lymphoblastic leukemia (ALL) treatment, with a cure rate of up to 90% when combined with l-asparaginase. Additionally, several antimetabolites, particularly those targeting nucleotide metabolism, have been approved for clinical use. Moreover, drugs targeting mutant isocitrate dehydrogenase in acute myeloid leukemia (AML) have marked a milestone in precision cancer metabolism therapy, demonstrating the potential effectiveness of metabolic treatment (10–12). Despite successes in tumor metabolism-targeted therapies, challenges such as significant toxicity and limited therapeutic windows remain, highlighting the need for more selective and safer agents. As research into the tumor immune microenvironment progresses, the interplay between metabolism and immune cells has garnered renewed attention (8). Future research may focus more on improving the tumor immune microenvironment by regulating metabolism, thereby enhancing the efficacy of tumor immunotherapy.
Due to its extensive clinical application experience and wide accessibility, traditional Chinese Medicine (TCM) plays a crucial role in cancer treatment in China (13). It has been reported that TCM can alleviate the side effects associated with conventional therapies and improve the prognosis of patients with various types of cancer (14, 15). Besides, many natural compounds have multi-target activities, which make them have the potential to regulate multiple metabolic pathways simultaneously or regulate both immune and metabolic related pathways, thereby synergistically enhancing their therapeutic effects. For instance, curcumin has demonstrated dual functions in cancer therapy by regulating both tumor metabolism and immune responses. It inhibits tumor cell proliferation through targeting key enzymes involved in the ROS metabolic pathway, while simultaneously exerting immunomodulatory effects by modulating immune cell activities and cytokine expression, including the suppression of TNF-α production and inhibition of dendritic cell maturation (16–18). Given these promising effects, these natural agents, with their lower toxicity profiles and broad spectrum of action, may provide a valuable strategy for overcoming the limitations of current tumor metabolism-targeted therapies.
Above all, targeting cancer metabolic abnormalities has been recognized as a promising strategy to remodel the tumor microenvironment and enhance antitumor immune responses. Meanwhile, traditional Chinese medicine, with its multi-target regulatory properties and immunomodulatory potential, has emerged as an important resource for the development of cancer immuno-sensitizers. Based on these insights, this study systematically reviews the latest advances in tumor metabolic reprogramming, the regulatory role of natural products in tumor metabolism, and emerging delivery and analysis technologies. It further explores the potential of natural metabolic modulators in improving the tumor immune microenvironment and enhancing immunotherapy sensitivity. These perspectives aim to provide new strategies and conceptual support for optimizing cancer immunotherapy by coordinating metabolic and immune regulation (Figure 1).
Figure 1. Targeting tumor metabolism with natural products to enhance immunotherapy.
2 Metabolic reprogramming of the tumor immune microenvironment
Glucose, lipid, and amino acid metabolism constitute the core energy and biosynthetic pathways essential for cellular function. Although often described independently, these metabolic processes are highly interconnected, with dynamic cross-regulation ensuring metabolic flexibility under stress. Within the tumor microenvironment, this cross-talk is further complicated by the coexistence of tumor and immune cells, both of which undergo metabolic reprogramming. Tumor and immune cells engage in metabolic competition and mutual modulation, shaping a metabolic landscape that profoundly influences tumor progression and immune responses. The following sections will provide an overview of the effects of the three major energy metabolic pathways on immune cells and tumor cells (Figure 2).
Figure 2. Metabolic reprogramming of glucose, amino acids, and lipids in the tumor immune microenvironment.
2.1 Warburg effect and glycolysis in cancer
Glucose metabolism is a central pathway for cellular energy production and biosynthesis. Through glycolysis, cells rapidly convert glucose into pyruvate, generating ATP and metabolic intermediates (19). Under aerobic conditions, pyruvate typically enters the mitochondria for oxidative phosphorylation (OXPHOS). However, cancer cells exhibit enhanced glycolysis even in the presence of oxygen, a phenomenon known as the Warburg effect (20). This metabolic reprogramming promotes tumor growth, enhances survival under hypoxic conditions, and contributes to resistance against various therapies (21, 22). The reprogramming of the glycolytic pathway involves not only changes in metabolic flux but also the regulation of the expression and activity of key enzymes. Among these, hexokinase (HK), phosphofructokinase (PFK), and pyruvate kinase M2 (PKM2) function as rate-limiting enzymes that directly determine the speed and direction of glycolysis. Regulation of these enzymes has been shown to play a critical role in the initiation and progression of various cancers, as well as in angiogenesis, immune evasion, and drug resistance (23, 24).
HK catalyzes the first irreversible step of glycolysis by phosphorylating glucose to glucose-6-phosphate. Studies have shown that HK2 is upregulated in various tumors, promoting cancer cell proliferation, invasion, and metastasis (25, 26). HK2 expression is elevated in both primary and metastatic lung cancers, and its upregulation can be suppressed by KRas deletion or overexpression of p53 and KEAP1 (27). Loss of HK2 inhibits migration and invasion of non-small cell lung cancer (NSCLC) cells, enhances cisplatin sensitivity, and reduces lung metastasis (28). In pancreatic ductal adenocarcinoma (PDAC), reduced HK2 expression inhibits VEGF-A signaling, thereby suppressing tumor growth and metastasis in mice (29). Glucose analogs such as 2-deoxy-D-glucose (2-DG) and 3-bromopyruvate (3-BrPA) can inhibit HK2, block glycolysis, and enhance the anticancer effects of other drugs, however, their toxicity limits clinical application (30, 31).
Phosphofructokinase-1 (PFK-1), another key rate-limiting enzyme of glycolysis, exists in three isoforms including PFKM, PFKL, and PFKP. Based on current researched, high PFKP expression is negatively correlated with overall survival in various cancers, including cervical, liver, and lung cancers (32). Tat activating regulatory DNA-binding protein (TARDBP) suppresses PFKP expression through miR-520, thereby inhibiting glycolysis and tumor growth in hepatocellular carcinoma (HCC) (33). Moreover, PFKP expression is upregulated in hepatocellular carcinoma, contributing to HCC proliferation and stemness maintenance (34). In brain tumors, EGFR mediates phosphorylation of PFKP at Y64, activating the PI3K signaling pathway and promoting proliferation (35).
The final step of glycolysis is catalyzed by pyruvate kinase (PK), which converts phosphoenolpyruvate (PEP) to pyruvate and generates ATP. Mammalian PK has four isoforms with distinct tissue distributions, PKM1 is predominantly expressed in normal adult cells favoring oxidative phosphorylation, while PKM2 is highly expressed in rapidly proliferating tumor and non-malignant cells, favoring glycolysis (36). PKM2 is significantly upregulated in colorectal cancer (CRC), inflammatory bowel disease, and intrahepatic cholangiocarcinoma (ICC), and is associated with higher tumor necrosis, angiogenesis, and advanced stages (37). High PKM2 expression is also linked to poor prognosis in multiple myeloma patients (38). Moreover, inhibiting PKM2 can enhance drug sensitivity; for instance, its interaction with CD44 promotes Thr105 phosphorylation, reducing PKM2 activity, elevating ROS, and sensitizing CRC cells to cisplatin. CD44 deficiency shifts glycolysis toward the TCA cycle, further increasing ROS and drug efficacy (39). Under hypoxia, IGF-1/IGF-IR promotes HIF-1α binding to NF-κB p65/RelA and the PKM2 promoter, while miR-148a/152 suppression upregulates PKM2. This induces PKM2 nuclear translocation, where it acts as a kinase to regulate VEGF expression and drive tumor angiogenesis (40).
Lactate dehydrogenase (LDH) has gained increasing attention for its significance in cancer. Elevated serum LDH levels, particularly in melanoma patients, are often associated with high tumor burden, poor prognosis, and unfavorable therapeutic outcomes. Although LDH is primarily used clinically as a prognostic biomarker reflecting tumor burden, growing evidence suggests that it also plays functional roles in tumorigenesis and progression (41). Pyruvate, the end product of glycolysis, is reduced to LDH to regenerate NAD+, thereby maintaining a high-flux glycolysis metabolic process. This metabolic reprogramming leads to the continuous production and accumulation of large amounts of lactate, which in turn causes acidification of the TME, promoting cancer cell growth, migration, and angiogenesis (42, 43). Moreover, Monocarboxylate transporters (MCT1 and MCT4), which regulate lactate transport across the cell membrane, are overexpressed in multiple cancers and help maintain the tumor microenvironment (44). Studies have shown that MCT4 knockdown or MCT inhibition reduces lactate uptake and migration in PDAC cells (45). Early studies also indicate that targeting MCT1 can suppress cancer cell growth and proliferation, and several small-molecule MCT1 inhibitors have been reported (46).
In addition, glucose transport plays a crucial role in regulating tumor glycolysis. Glucose transporters (GLUTs) are commonly expressed on cell membranes, with GLUT1 being the most widely distributed isoform. Meta-analyses have shown that GLUT1 is frequently overexpressed in various solid tumors and is associated with poor prognosis (47). Moreover, the GLUT1 inhibitor BAY-876 has been reported to significantly reduce glucose uptake, cell viability, and metabolic activity in head and neck squamous cell carcinoma (HNSCC), while also inducing apoptosis (48).
In summary, the upregulation of key glycolytic enzymes such as HK, PFK, and PKM2, as well as LDH and lactate transporters MCT1 and MCT4, along with increased expression of the glucose transporter GLUT1, enhances glycolytic activity in tumors, contributes to an acidic TME, and promotes cancer cell invasion and migration.
2.2 Amino acid metabolism reprogramming in cancer
To support rapid proliferation under nutrient-deprived microenvironments, tumor cells undergo extensive metabolic reprogramming, often adopting the “use of opportunistic modes of nutrient acquisition” strategy (49). In addition to altered glucose metabolism, dysregulated amino acid metabolism has emerged as a key hallmark of cancer. Amino acids serve not only as building blocks for protein synthesis but also as vital sources of carbon and nitrogen, contributing to energy production, redox balance, and the regulation of multiple signaling pathways—including mTORC1, MYC, and KRAS—that drive tumor progression. Furthermore, certain amino acid-derived metabolites, such as α-ketoglutarate (α-KG), acetyl-CoA, NAD+, and S-adenosylmethionine (SAM), modulate gene expression through epigenetic mechanisms (50). Collectively, these processes form a complex metabolic network that provides a rationale for targeting amino acid metabolism in cancer therapy. Compared with normal cells, tumor cells exhibit enhanced dependence on amino acids, with heterogeneous requirements across different cancer types (51). The heterogeneous dependence of tumor cells on specific amino acids makes amino acid metabolism a key target for anti-cancer therapy. Restricting essential amino acids may starve cancer cells, while supplementing certain amino acids in specific contexts may enhance therapeutic efficacy, highlighting the complexity and precision required in metabolic interventions.
Among amino acid-targeted therapies, asparagine (Asn) remains the most well-established and clinically effective target for amino acid depletion therapy. In pediatric ALL, bacterially derived asparaginase (ASNase) markedly improved cure rates (52). Glutamine is the most abundant amino acid in plasma and the most rapidly consumed in tumors (53). Tumor cells show “glutamine addiction”, and its deficiency often arrests cancer cells in the S phase (54). ASCT2 (SLC1A5) is the major glutamine transporter in tumors, and studies have found that its high expression is associated with poor prognosis in a variety of tumors (55). SLC1A5 is a key target in glutamine metabolism, but current inhibitors show limited specificity. While V-9302 and new monoclonal antibodies demonstrate promise in preclinical models, especially in colorectal cancer, effective and selective inhibitors for broader clinical use remain scarce (56). Serine is a central metabolite involved in the synthesis of proteins, amino acids, and nucleotides. Cancer cells fulfill their serine demand either through exogenous uptake or via de novo synthesis, thereby fueling the serine–glycine–one-carbon (SGOC) metabolism pathway. This pathway is critical for tumorigenesis and holds substantial clinical significance (57). Preclinical studies have shown that dietary restriction of serine and glycine significantly inhibits tumor proliferation in mouse models of intestinal cancer and lymphoma (58). Moreover, serine deprivation can induce ROS production, activate the AMPK pathway, and remodel the cytoskeleton to enhance cancer cell motility. Inhibition of serine/glycine uptake or knockdown of SHMT1 suppresses the migration of lung adenocarcinoma cells (59, 60). Moreover, other amino acids, such as arginine, methionine, and others, have also been widely implicated in tumor metabolic reprogramming (50, 61). Notably, amino acid supplementation may exhibit anti-tumor effects in specific contexts. Ishak Gabra et al. reported that glutamine supplementation inhibited melanoma growth by modulating epigenetic reprogramming (62). In line with this, histidine supplementation increased the sensitivity of leukemia xenograft models to methotrexate (63).
Dysregulated amino acid metabolism is crucial for tumor growth, offering both metabolic support and regulatory control. The varying amino acid dependencies across cancers highlight the potential of targeting these pathways. Strategies involving amino acid depletion or supplementation have shown context-dependent anti-tumor effects, underscoring the need for precise metabolic interventions in cancer therapy.
2.3 Lipid metabolic reprogramming in cancer
Lipids represent a structurally diverse group of biomolecules, classically categorized into fatty acids (FAs), glycerol-based lipids (including neutral triacylglycerols and phosphoglycerides), and non-glycerol-based lipids (such as sterols and sphingolipids). Except for severing as an energy source via fatty acid oxidation (FAO), lipids are essential for maintaining cellular membrane integrity and mediating a wide array of signal transduction processes (64). In the tumor microenvironment, lipid metabolism undergoes profound reprogramming to support the demands of uncontrolled proliferation and survival (65). This metabolic adaptation ensures a continuous supply of lipid precursors for membrane biosynthesis, facilitates ATP production through enhanced fatty acid oxidation, and generates lipid-derived signaling molecules that function as second messengers in multiple oncogenic pathways. Moreover, dysregulated lipid metabolism influences key tumor-associated biological processes, including endoplasmic reticulum (ER) stress responses and ferroptosis (66, 67). As such, inhibition of lipid biosynthetic pathways has been recognized as a potential therapeutic strategy for impairing tumor growth and viability.
Fatty acid metabolism, including de novo synthesis and FAO plays a crucial role in supporting tumor growth, progression, and therapy resistance. Fatty acid synthase (FASN), a key enzyme in de novo lipogenesis, catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA precursors. Upregulation of FASN has been widely reported across multiple malignancies, including colorectal, prostate, ovarian, gastrointestinal, lung cancer, et al., (68). Notably, hypoxic TMEs induce the overexpression of hypoxia-inducible factor 1-alpha (HIF-1α), which in turn promotes the transcription of lipid-associated genes, such as lipid transporters, FASN, and sterol regulatory element-binding protein 1 (SREBP1). This coordinated upregulation facilitates enhanced lipid uptake, transport, and synthesis, ultimately contributing to the proliferation and migration of cancer cells, as observed in HCT-116 colorectal cancer cells (69). In addition to de novo lipogenesis, FAO is often upregulated in tumors to meet the high energy demands of rapidly proliferating cells. FAO is regulated by a series of fatty acid oxidases and is closely linked to cancer cell invasiveness (70). Carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme in FAO, facilitates the mitochondrial transport of long-chain fatty acids for β-oxidation. Inhibition of CPT1-mediated FAO has been shown to sensitize tumor cells to chemotherapy- or immunotherapy-induced cell death, highlighting its potential as a therapeutic target (71). Moreover, CD36, a membrane-associated lipid transporter, promotes cancer cell migration by enhancing fatty acid uptake and activating FAO (72).
Phospholipids are important components of cell membranes and play an important role in maintaining cell membrane structure and normal function as well as regulating signal transduction and cell cycle. Alterations in phosphoglyceride metabolism in cancer can be attributed to dysregulation of rate-limiting enzymes involved in phosphoglyceride metabolism, which are critical for tumor growth. Phospholipase A2 (PLA2) is a phospholipid metabolizing enzyme that releases free fatty acids, mostly arachidonic acid, and lysophospholipids, which contribute to the development of the TME, promoting immune evasion, angiogenesis, tumor growth, and invasiveness (73). Studies have reported that in stage II colorectal cancer, patients with PLA2-negative tumors have significantly longer disease-free survival, suggesting that PLA2 may be a prognostic predictor for colorectal cancer (74). Moreover, In colorectal cancer, inhibition of PLD activity suppresses PA production and inactivates mTOR signaling, thereby interfering with cancer cell proliferation (64). In addition, phospholipid metabolites are also essential for the biological functions of cells. Arachidonic acid is an important phospholipid metabolite that is associated with carcinogenesis. PIK3CA mutant tumor cells transmit oncogenic signals and result in malignant transformation of intestinal epithelial cells (IECs) via paracrine exosomal arachidonic acid (AA)-induced H3K4 trimethylation (75). Other studies have found that arachidonic acid metabolism inhibitors synergize with immune checkpoint inhibitors to inhibit the growth of ARID1A-deficient colorectal cancer by enhancing CD8+ T cell activity and inhibiting vasculogenic mimicry (76).
Besides, cholesterol also plays an important role in cancer development. Both clinical and experimental studies have found that hypercholesterolemia and a high-fat, high-cholesterol diet can affect cancer development. External cholesterol can directly activate the oncogenic Hedgehog pathway, and internal cholesterol can induce mTORC1 signaling (76). Cholesterol is not only a precursor of hormones such as vitamin D, progesterone, and estrogen, but also participates in the formation of lipid rafts, which are important platforms for the regulation of multiple oncogenic signaling pathways (77).
2.4 Effects of metabolism on immune cells in the TME
Tumor-infiltrating immune cells have dual characteristics, some of which have the function of inhibiting tumor proliferation and metastasis, such as CD8+ cytotoxic T cells, natural killer (NK) cells, M1 macrophages, dendritic cells (DCs), etc., while others may be beneficial to tumor development, including Treg cells, M2 macrophages (78). The TME, characterized by nutrient deficiency, lactate accumulation, lipid deposition, and hypoxia, significantly impairs immune function and weakens anti-tumor responses (79). In addition, studies have found that certain metabolites in the TME can suppress immune activity. In response to these challenges, immune cells also adjust their metabolic processes to resist tumor progression (80).
The proliferation of tumor cells and immune cells depends on glycolysis, and tumor cells compete for glucose, which makes immune cells lack nutrients and unable to perform their functions (81). Furthermore, the expression of the key glycolytic enzyme PFKFB3 is upregulated and mediates increased PD-L1 expression by activating the nuclear factor κB signaling pathway, thereby inhibiting the anti-tumor activity of cytotoxic CD8+ T lymphocytes (82). In addition, metabolic byproducts produced during glycolysis, such as lactate, significantly inhibit anti-tumor immune responses. Lactic acid interferes with the differentiation of monocytes and DCs, thereby hindering antigen presentation and immune priming (83). In regulatory T cells, lactate is taken up by MCT1 and activates the nuclear translocation of NFAT (nuclear factor of activated T cells), thereby upregulating the expression of programmed cell death protein 1 (PD-1) and enhancing its immunosuppressive activity (84). Lactic acid promotes the polarization of tumor-associated macrophages (TAMs) into a pro-tumor M2-like phenotype, and this lactate-induced M2 polarization facilitates pituitary adenoma invasion by enhancing CCL17 secretion (85). Moreover, lactic acid can promote immune evasion by suppressing the function of NK cells through inhibition of nuclear factor of activated T cells (NFAT) in NK cells (85).
When glucose availability is limited within the TME, tumor-infiltrating immune cells may undergo metabolic reprogramming to sustain their functional capacity, notably by increasing the uptake and oxidation of fatty acids (FA). Currently, the impact of lipid metabolism on immune cell function has been extensively discussed. For instance, lipid accumulation in the TME drives CD8+ T cell dysfunction via the CD36 receptor. CD36 mediates the uptake of oxidized lipids, leading to lipid peroxidation and p38 kinase activation, which impair T cell function (86). Moreover, intracellular lipid accumulation or supplementation with exogenous fatty acids can trigger the generation of reactive oxygen species (ROS) and the secretion of immunosuppressive cytokines, thereby facilitating the polarization of macrophages toward a pro-tumorigenic M2 phenotype, which in turn enhances tumor cell invasiveness and metastatic potential (87). In addition, studies have reported that abnormal lipid accumulation in the TME leads to decreased antigen presentation ability of DCs and anti-tumor ability of T cells (88).
In the TME, tumor cells have significantly higher metabolic activity than normal cells and competitively inhibit the uptake of amino acids by immune cells, thereby inhibiting antitumor immune activity (50).
For example, increased tumor uptake of glutamine similarly limits its availability to T cells, impairing the proliferation and activation of especially effector T cells. During glutamine deprivation, Teff cells show decreased c-MYC protein expression, growth restriction, and impaired immune function (89). In addition, glutamine deprivation promotes the differentiation of Treg cells through AMPK-mTORC1 signaling pathway, thereby reducing the immune function of Teff cells (90). Moreover, Tryptophan is an essential amino acid that is only obtained through diet and is rapidly depleted in the TME due to increased consumption and catabolism by tumor cells. Tumor cells metabolize tryptophan to kynurenine, which is a ligand for the aryl hydrocarbon receptor (AHR). AHR activation in CD4+ T cells promote their differentiation into immunosuppressive regulatory T cells (Tregs), while kynurenine also induces PD-1 expression on CD8+ T cells, inhibiting their cytotoxic function (91). Based on current studies, arginine deprivation further compromises T cell function by reducing mTORC1 activity, leading to an increased proportion of memory-like T cells while diminishing effector functions and immune surveillance (92). Additionally, M2-like TAMs upregulate arginase 1 (Arg1), enhancing arginine metabolism and further depleting extracellular arginine, thereby exacerbating immunosuppression (93).
In summary, the harsh metabolic landscape of the TME, characterized by nutrient competition, accumulation of immunosuppressive metabolites, and dysregulated lipid and amino acid metabolism, severely impairs the function and fate of infiltrating immune cells, ultimately promoting tumor immune evasion and progression. Understanding these metabolic interactions offers important therapeutic opportunities to restore antitumor immunity and improve cancer treatment outcomes.
2.5 Integrated immunometabolic targets and technological advances in the tumor microenvironment
Metabolic reprogramming drives the formation of an immunosuppressive TME through multiple mechanisms, thereby promoting cancer progression and diminishing the efficacy of anticancer immunotherapies. Within the TME, nutrient scarcity—particularly of glucose and amino acids—combined with the accumulation of immunosuppressive metabolites such as lactate, adenosine, and kynurenine creates a metabolic niche that impairs the function of antitumor immune cells. However, traditional metabolic profiling approaches—such as tissue homogenization coupled with gas chromatography- mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS)—despite their success in identifying tumor-specific metabolic signatures, discovering prognostic biomarkers, and revealing adaptive metabolic responses under therapeutic stress limited (94). These methods disrupt cellular spatial architecture, overlook cell–cell interactions, and perturb the native metabolic state, thus failing to capture the full spatiotemporal heterogeneity of metabolism within the tumor-immune ecosystem.
Recent advances in single-cell sequencing and spatial metabolomics have provided transformative solutions to long-standing challenges in understanding tumor heterogeneity and therapeutic resistance. The advent of single-cell technologies now enables the interrogation of metabolic states at the resolution of individual immune cells within clinical tumor samples, revealing pronounced context-dependent metabolic heterogeneity across immune cell subset (95, 96). In parallel, matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI–MSI) allows label-free, near–single-cell-resolution mapping of thousands of metabolites directly in intact tissue sections while preserving spatial architecture (97, 98). Application of MALDI–MSI across diverse malignancies—including colorectal, lung, breast, liver, and brain tumors—has uncovered spatially organized metabolic gradients associated with hypoxia, immune infiltration, stromal composition, and therapeutic response, thereby providing mechanistic insights into regional immune suppression and functional divergence of immune cells within the TME (98, 99).
Moreover, the integration of single-cell transcriptomics with spatial metabolomics, together with complementary genomic, proteomic, and epigenomic data, enables a systematic, multi-dimensional reconstruction of tumor–immune interactions. Such integrative approaches reveal how dynamic metabolic remodeling within the TME—including hypoxia, nutrient deprivation, and immunosuppressive metabolite accumulation—reshapes immune cell states and fosters therapeutic resistance. Beyond tumor cell–intrinsic mechanisms such as genomic instability and aberrant signaling, this spatially resolved, single-cell multi-omics framework highlights the critical role of TME-driven immune metabolic reprogramming in mediating resistance to chemotherapy, targeted therapy, and immunotherapy.
3 Natural products targeting tumor metabolism
Although a variety of chemotherapeutic and molecularly targeted agents have been developed to inhibit key metabolic enzymes, their clinical application is often limited by modest efficacy, drug resistance, and severe adverse effects. In contrast, natural products have attracted increasing attention as promising candidates owing to their multitarget regulatory properties, relatively low toxicity, and ability to modulate the tumor microenvironment. These compounds exert comprehensive regulatory effects on tumor metabolism, including the modulation of glycolysis, lipid metabolism, and oxidative phosphorylation. Table 1 provides a summary of representative natural products and their corresponding metabolic target.
Table 1. Natural products modulating metabolic enzymes and pathways in cancer.
3.1 Regulation of glycolysis
As mentioned above, key glycolytic enzymes such as HK, PFK, and PKM2, along with LDH, lactate transporters MCT1 and MCT4, and the glucose transporter GLUT1, are critical for tumor proliferation and metastasis. Current studies have revealed that many natural products exert significant regulatory effects on these proteins and enzymes, thereby contributing to their antitumor activities. Studies have demonstrated that curcumin downregulates HK2, leading to mitochondrial dysfunction and apoptosis in CRC cells (100). EGCG (epigallocatechin gallate, a green tea polyphenol) disrupts the binding of HK2 to mitochondria, thereby impairing energy metabolism and inducing apoptosis (101). Arsenic trioxide (As2O3) inhibits HK2 expression and glycolysis in cancer cells, triggering apoptosis (102). Besides, phloretin suppresses GLUT2 expression by blocking the transcription factor HNF6 and additionally activates the p53 pathway, promoting cell cycle arrest and apoptosis (103). Apigenin downregulates GLUT1 via inhibition of HIF-1α, leading to reduced VEGF secretion and exhibiting both antiproliferative and antimetastatic effects (104). Trehalose suppresses glucose transport by inhibiting glucose transporter activity, inducing a starvation-like state characterized by ATP depletion. This metabolic stress activates autophagy through AMPK-dependent signaling, thereby exerting anticancer effects (105). Genistein suppresses GLUT1 and HK2 expression by downregulating HIF-1α (106), induces cell cycle arrest, and reduces the invasive capacity of CRC cells (107). Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin (108). Shikonin selectively inhibits PKM2, decreasing glucose consumption and promotes the release of lactate in MCF-7 and A549 tumor model (109). Similarly, Lapachol is a potent PKM2 inhibitor that inhibits glycolysis and reduces ATP production in melanoma cells. Lapachol also effectively sensitizes cells to mitochondrial proton transporters, promoting apoptosis and antiproliferative effects (110). Gossypol inhibits LDHA, lowering lactate production and glycolytic flux while inducing apoptosis (111). Oxamate, another LDHA inhibitor, induces mitochondrial apoptosis in cancer cells by suppressing lactate production. A study showed that Oxamate exhibits synergistic antitumor effects in preclinical models when combined with metformin or mTOR inhibitors (112). Moreover, in TCM, oleanolic acid (OA), a triterpenoid compound abundant in Oleaceae plants, has emerged as a potential therapeutic candidate for gastric cancer (113). OA regulates aerobic glycolysis and tumor cell proliferation by downregulating HIF-1α, HK2, and PFK1, thereby suppressing glucose uptake and utilization, inhibiting cell growth, and reducing intracellular lactate levels (114).
3.2 Modulation of lipid metabolism
As noted above, lipid metabolism—including fatty acid, phospholipid, and cholesterol metabolism—plays a critical role in tumor development and progression. A number of natural products have been reported to exert anticancer effects by modulating key enzymes and signaling pathways involved in lipid metabolism. For example, both luteolin and resveratrol inhibit FASN. In HT-29 cells, luteolin downregulates anti-apoptotic proteins and induces cell cycle arrest (115). Resveratrol modulates lipid metabolism in cancer through multiple mechanisms, thereby restoring a metabolic balance more compatible with physiological demands. Specifically, resveratrol inhibits lipid synthesis via suppression of SREBPs, activates sirtuins in concert with AMPK activation, and downregulates the PI3K/AKT/mTOR pathway, ultimately leading to cancer cell apoptosis. Clinically, resveratrol has been shown to reduce tumor burden and metastasis by decreasing serum TAG, VLDL, and LDL levels in cancer patients, suggesting its potential role in modulating cancer initiation and progression (116). In addition, curcumin inhibits ACLY activity, thereby lowering acetyl-CoA levels, reducing lipid biosynthesis, and suppressing tumor growth (117). Similarly, berberine suppresses ACLY activity, contributing to the inhibition of tumor progression and metastasis (118). Furthermore, naringenin regulates cholesterol metabolism by reducing foam cell formation, decreasing intracellular cholesterol levels and esterification, and enhancing cholesterol efflux in THP-1 macrophages (119). Taken together, these findings highlight that natural products not only regulate glycolysis and mitochondrial function but also reprogram lipid metabolism, thereby exerting multifaceted anticancer effects through the coordinated targeting of multiple metabolic pathways.
3.3 Modulation of amino acid metabolism
Amino acid metabolism provides both metabolic substrates and regulatory signals critical for tumor growth. Distinct amino acid dependencies across cancers highlight therapeutic potential. Strategies involving amino acid depletion or supplementation show context-dependent antitumor effects. TCMs also regulate amino acid metabolism: Huangqin Tang (HQT) alleviates and delays colitis-associated cancer (CAC) by maintaining amino acid homeostasis and modulating the PI3K/AKT/mTOR pathway, thereby balancing proliferation and apoptosis (120). Early administration of Wu Mei Wan (WMW) prevents CAC development by suppressing myeloid-derived suppressor cells through regulation of amino acid metabolism and the PI3K/Akt pathway (121). The aqueous extract of Kudingcha inhibits the expression of glycerol-3-phosphate dehydrogenase, disrupts amino acid metabolism, induces mitochondrial oxidation in breast cancer cells, and the resulting ROS reverse the epithelial mesenchymal transition process (122). In addition, licorice root extract (123) and modified Si Jun Zi Tang (124) have been demonstrated, in both in vitro and in vivo studies, to regulate multiple metabolic pathways, including glycolysis and glutamine, serine, and glycine-related metabolism, thereby influencing cancer cell proliferation, apoptosis, and migration.
3.4 Targeting mitochondrial function and oxidative stress
Mitochondrial dysfunction plays a crucial role in tumor-induced immunosuppression. Aberrant mitochondrial metabolism and excessive reactive ROS production remodel the TME, thereby weakening effective antitumor immune responses (125). In addition, studies have revealed that certain natural compounds can induce tumor cell death by targeting mitochondrial function and enhancing oxidative stress. For instance, rhein–DCA accumulates in mitochondria, where it inhibits glycolysis through the PDK–PDH axis and disrupts the respiratory chain, thereby inducing oxidative stress, reducing lactate levels, and promoting cell death in CRC models (126). Frondoside A downregulates Bcl-2 and survivin, increases ROS production, and promotes cytochrome c release, ultimately triggering mitochondrial apoptosis c release, ultimately triggering mitochondrial apoptosis (127). Ginsenoside Compound K activates ROS-mediated mitochondrial apoptosis, leading to cytochrome c release and the activation of caspase-9/-3 (128). Resveratrol (RES) reprograms energy metabolism in colorectal cancer cells by enhancing oxidative phosphorylation, suppressing glycolysis and the pentose phosphate pathway, and increasing ATP production. In addition, it acts on the mitochondrial pyruvate dehydrogenase (PDH) complex to boost PDH activity, with calcium signaling and the CamKKB/AMPK pathway mediating the enhancement of glucose oxidation. These effects collectively shift cancer cell metabolism toward a more oxidative, energy-efficient state (129). In summary, natural products such as oleanolic acid, resveratrol, and curcumin embody the hallmarks of multi-target metabolic regulation by simultaneously regulating glycolysis, mitochondrial function and oxidative stress, lipid metabolism, and amino acid metabolism, highlighting their unique ability to reprogram tumor metabolism and exert comprehensive anticancer effects. This multi-target metabolic reprogramming highlights the therapeutic potential of natural compounds in comprehensive cancer intervention.
Overall, the natural products discussed in this section encompass both TCM formulas and single compounds, including their derived bioactive monomers. TCM formulas, such as HQT and WMW, achieve system-level regulation of tumor metabolic reprogramming through synergistic multi-component, multi-target, and multi-pathway effects, thereby inhibiting cancer cell growth, invasion, and migration. However, the complexity of these formulations, which often contain hundreds of chemical constituents, poses challenges for standardization and mechanistic elucidation. In contrast, single compounds like curcumin and resveratrol demonstrate well-defined antitumor immunomodulatory activities by modulating immune cell activation, functional maintenance, and cytokine production. Due to their clearly characterized chemical structures and target specificity, these monomeric compounds offer distinct advantages for mechanistic studies of tumor metabolism and immune regulation.
4 Natural products in cancer immunotherapy: metabolic reprogramming, immune activation, and advanced delivery strategies
Accumulating evidence indicates that natural products exert broad immunomodulatory effects making them promising adjuvants in cancer immunotherapy. Within the tumor microenvironment, natural compounds can reprogram dysregulated immune cell metabolism, restore antitumor immune function, and alleviate immunosuppressive signaling. Moreover, many natural products enhance immune activation by inducing immunogenic cell death and modulating immune checkpoint pathways, thereby improving responses to immune checkpoint inhibitors. However, their clinical translation is often limited by poor bioavailability and inadequate tumor targeting. Recent advances in delivery technologies, particularly nanotechnology-based systems, provide effective strategies to enhance stability, targeting efficiency, and therapeutic efficacy.
4.1 Natural products remodel tumor microenvironment through immune cell metabolic reprogramming
With increasing insights into the mechanisms by which natural products modulate metabolism in cancer, studies have found that these natural products have the potential to reshape the TME by reprogramming immune cell metabolism and restoring antitumor immunity.
As mentioned above, RES exerts multi-target metabolic regulatory effects in cancer cells. Moreover, current study showed that RES directly reprograms T cell metabolism in the TME. Low-dose RES (20 µM) downregulates GLUT1, decreasing glucose uptake, glycolysis, lactate production, and extracellular acidification, while enhancing glutamine metabolism through upregulation of ASCT2 and GLS2. These changes shift energy metabolism from glycolysis toward OXPHOS, increase ATP levels and mitochondrial ROS, and activate p53 via ATR-dependent stress signaling. Importantly, these metabolic effects enhance IFN-γ secretion and T cell effector functions, demonstrating that RES-mediated metabolic reprogramming can strengthen antitumor immunity (130, 131). Clinical studies investigating resveratrol in cancer remain limited but span multiple tumor types, including colorectal, liver, breast, and colon cancers, as well as multiple myeloma and other solid tumors. Early-phase trials (e.g., NCT00433576, NCT00256334) demonstrated acceptable safety and tissue bioavailability at moderate doses, whereas high-dose formulations such as SRT501 in multiple myeloma (NCT00920556) caused renal toxicity, highlighting dose-related safety concerns. Most studies focused on pharmacokinetics, biomarker modulation, and metabolic effects rather than therapeutic efficacy. These findings suggest that while resveratrol exhibits promising immunometabolic regulatory potential, further well-designed randomized clinical trials are required to establish its clinical benefits in oncology (Table 2).
Table 2. Summary of Clinical Trials Investigating Resveratrol in Cancer and Tumor-Related Conditions.
Furthermore, research by Carrasco-Pozo C et al. (132), demonstrated that gut microbiota metabolites derived from dietary polyphenols (e.g., quercetin, proanthocyanidins, and kaempferol), such as 3,4-dihydroxyphenylacetic acid (3,4-DHPAA) and 4-hydroxyphenylacetic acid (4-HPAA), can counteract the immunosuppressive effects of heme on macrophages. Heme induces an anti-inflammatory phenotype via HO-1, suppresses glycolysis, reduces IP-10 production, and impairs macrophage phagocytosis and tumor cell killing. Both 3,4-DHPAA and 4-HPAA restore glycolytic activity, upregulate enzymes involved in glycolysis and the pentose phosphate pathway, and stabilize HIF-1α, thereby recovering macrophage inflammatory responses, phagocytosis, and cytotoxicity toward tumor cells (133). In addition, although some studies have not directly explored metabolic regulation within the TME, they have explored how natural products can improve immune cell metabolism and thus affect immune function. For example, studies have reported that dioscin promotes FAO in macrophages through the mTORC2/PPAR-γ pathway (134). Similarly, curcumin modulates lipid metabolism in THP-1-derived macrophages by upregulating lipid transport genes such as CD36/FAT and FABP-4, leading to lipid accumulation and potentially limiting lipid utilization by tumor cells, ultimately inhibiting tumor growth (135, 136).
Collectively, these findings highlight that natural products, either directly or via microbial metabolism, can reprogram immune cell metabolism-targeting glycolysis, the pentose phosphate pathway, and lipid metabolism-to restore immune activity and enhance antitumor responses within the TME.
4.2 Natural products enhance antitumor immunotherapy
Accumulating evidence indicates that natural products exert multifaceted immunomodulatory effects within the TME, thereby enhancing antitumor immunity and improving the efficacy of cancer immunotherapies (137). A growing number of natural compounds have been shown to induce immunogenic cell death (ICD), a process characterized by the exposure or release of damage-associated molecular patterns (DAMPs), such as calreticulin (CRT), high-mobility group box 1 (HMGB1), and heat shock proteins (HSPs) (138). To date, only a limited number of agents have been shown to induce ICD, yet accumulating evidence indicates that several natural products possess this capacity. Compounds such as capsaicin (139, 140), ginsenoside Rg3 (140), resveratrol (141), and the combination of quercetin with alantolactone (142)can trigger ICD by promoting the exposure or release of DAMPs, including calreticulin, heat shock proteins, and HMGB1. These events enhance dendritic cell uptake, maturation, and antigen presentation, leading to robust CD8+ T cell–mediated antitumor immune responses and long-term immune memory. In addition, some natural products, such as shikonin, function as potent adjuvants for dendritic cell–based tumor vaccines by further amplifying ICD-associated immunogenicity (143). Collectively, these findings demonstrate that natural products can convert dying tumor cells into “in situ cancer vaccines,” highlighting their potential as immune-enhancing agents in cancer immunotherapy.
In addition to enhancing immune priming, several natural products directly regulate immune checkpoint pathways and immunosuppressive networks within the TME. Compounds such as, baicalin (144), silibinin (145), panaxadiol (146), and Bu-zhong-yi-qi decoction (147) have been shown to downregulate PD-1 or PD-L1 expression through modulation of upstream signaling pathways, including JAK–STAT, NF-κB, and PI3K–AKT–mTOR signaling. Unlike monoclonal antibodies that physically block PD-1/PD-L1 interactions, these agents reprogram the immunosuppressive milieu by simultaneously affecting tumor cells, tumor-associated macrophages, regulatory T cells, and inflammatory cytokine networks. Consistent with these mechanisms, increasing preclinical evidence demonstrates that natural products can synergize with immune checkpoint inhibitors (ICIs) to overcome therapeutic resistance. For instance, andrographolide enhances anti–PD-1 efficacy by suppressing COX-2/PGE2–mediated immunosuppression (148), whereas diosgenin potentiates the activity of anti–PD-1 antibodies by promoting T cell infiltration through modulation of the gut microbiota (149). Moreover, Xu et al. demonstrated that puerarin enhances anti–PD-L1 efficacy by suppressing ROS production, thereby reducing CAF-mediated physical barriers, increasing T-cell infiltration, and alleviating immunosuppression in the tumor microenvironment (150).
Collectively, these findings underscore the unique capacity of natural products to modulate tumor–immune crosstalk at multiple levels, ranging from immune priming and checkpoint regulation to metabolic and microbial reprogramming. By virtue of their multi-target, low-toxicity, and system-level regulatory properties, natural products represent promising adjuvant agents for combination immunotherapy strategies aimed at enhancing efficacy, mitigating resistance, and improving long-term clinical outcomes.
4.3 Advanced delivery systems for natural products
Recent advances in nanotechnology-based drug delivery systems have provided powerful solutions to the long-standing translational barriers of natural products, particularly poor solubility, limited bioavailability, and non-specific tissue distribution. A wide range of nano-drug delivery systems (NDDS), including lipid nanoparticles, nanoliposomes, polymeric micelles, nanosuspensions, and self-microemulsifying systems, have been developed to enhance the pharmacokinetic stability and therapeutic efficacy of bioactive natural compounds (151). These nanoformulations improve aqueous solubility, protect labile molecules from degradation, prolong systemic circulation, and enable passive or active tumor targeting via the enhanced permeability and retention (EPR) effect or ligand-mediated delivery (152). Moreover, nano-delivery platforms enable co-encapsulation of natural products with chemotherapeutic or immunotherapeutic agents, facilitating synergistic immunomodulatory effects and improving responses to immune checkpoint blockade (153).
For instance, Curcumin exhibits poor stability under physiological conditions, limiting its clinical translation. Chen et al. developed a nanoencapsulated formulation that achieved targeted delivery while improving chemical stability (154). Besides monotherapy, nanoplatforms also facilitate synergistic combination drug strategies. Zhang et al. co-encapsulated docetaxel and resveratrol in liposomes, achieving synergistic antitumor efficacy against prostate cancer by simultaneously inducing tumor cell apoptosis and regulating the tumor microenvironment (153). Xiao et al. reported a novel nanoparticle system functionalized with anti–PD-1 antibodies and loaded with curcumin, featuring dual pH responsiveness. Compared with free curcumin, this nanoformulation significantly enhanced cellular uptake. In addition to benefiting from the EPR effect, surface conjugation of anti–PD-1 antibodies facilitated specific binding of the nanoparticles to PD-1+ T cells. Owing to their pH-sensitive properties, these nanoparticles exhibited increased tumor selectivity, enabling greater intratumoral delivery of curcumin. This dual-delivery strategy effectively co-localized anti–PD-1 antibodies and curcumin within tumors and demonstrated superior therapeutic efficacy in both in vitro and in vivo models (155).Collectively, these technological advances highlight nanotechnology-based delivery as a critical and clinically relevant strategy to bridge the gap between the promising immunometabolic activities of natural products and their successful translation into cancer immunotherapy.
5 Conclusion and future perspectives
Natural metabolism-regulating agents have emerged as promising adjuvant strategies in cancer immunotherapy due to their ability to reprogram metabolic pathways and restore antitumor immunity. Notably, the complex composition of traditional Chinese medicine warrants careful consideration when used in combination with immunotherapy, as excessive immune activation may trigger immune-related adverse events, and certain traditional Chinese medicines with hepatotoxic potential may increase the risk of organ injury during combination treatment. However, clinical translation remains challenging, with key issues including dose optimization, safety evaluation, and patient selection. Although several natural compounds have entered preclinical or early clinical trials, the transition from bench to bedside is often hindered by limited pharmacokinetic stability, unclear mechanisms of action, and heterogeneous patient responses.
Looking ahead, precision targeting of specific metabolic pathways offers substantial therapeutic potential, particularly when integrated with advances in immunotherapy. Progress in this field will require close interdisciplinary collaboration among pharmacology, immunology, and metabolism research, as well as innovative approaches to identify novel compounds, such as immune-sensitizing agents from traditional Chinese medicine. Future studies should focus on elucidating the intricate interplay between metabolism and the immune system to design more selective and effective therapeutic strategies. Addressing translational barriers and validating natural products in rigorous clinical settings will be essential steps toward realizing their clinical application and therapeutic promise.
Author contributions
XF: Writing – review & editing, Writing – original draft, Conceptualization. SG: Writing – review & editing, Investigation. WL: Writing – review & editing, Conceptualization. YW: Supervision, Data curation, Writing – review & editing. JB: Supervision, Data curation, Writing – review & editing. JH: Formal analysis, Conceptualization, Writing – review & editing, Investigation. HJ: Supervision, Writing – review & editing, Project administration, Validation.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Natural Science Foundation of China (82074104) and the National Natural Science Foundation of China (22177134).
Conflict of interest
Authors WL, YW, JB, JH, and HJ were employed by Beijing Union-Genius Pharmaceutical Technology Development Co. Ltd.
The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660
2. Zhang Y and Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. (2020) 17:807–21. doi: 10.1038/s41423-020-0488-6
3. Wu B, Zhang B, Li B, Wu H, and Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. (2024) 9:274. doi: 10.1038/s41392-024-01979-x
4. Elmusrati A, Wang J, and Wang CY. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. (2021) 13:24. doi: 10.1038/s41368-021-00131-7
5. Shen KY, Zhu Y, Xie SZ, and Qin LX. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. (2024) 17:25. doi: 10.1186/s13045-024-01549-2
6. Micevic G, Bosenberg MW, and Yan Q. The crossroads of cancer epigenetics and immune checkpoint therapy. Clin Cancer Res. (2023) 29:1173–82. doi: 10.1158/1078-0432.CCR-22-0784
7. Kroemer G and Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ Heel. Cancer Cell. (2008) 13:472–82. doi: 10.1016/j.ccr.2008.05.005
8. De Martino M, Rathmell JC, Galluzzi L, and Vanpouille-Box C. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. (2024) 24:654–69. doi: 10.1038/s41577-024-01026-4
9. Leone RD and Powell JD. Fueling the revolution: targeting metabolism to enhance immunotherapy. Cancer Immunol Res. (2021) 9:255–60. doi: 10.1158/2326-6066.CIR-20-0791
10. Li Y, Tang J, Jiang J, and Chen Z. Metabolic checkpoints and novel approaches for immunotherapy against cancer. Int J Cancer. (2022) 150:195–207. doi: 10.1002/ijc.33781
11. DeBerardinis RJ, Vousden KH, and Chandel NS. Cancer metabolism: aspirations for the coming decade. Cold Spring Harb Perspect Med. (2024):a041555. doi: 10.1101/cshperspect.a041555
12. Stine ZE, Schug ZT, Salvino JM, and Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. (2022) 21:141–62. doi: 10.1038/s41573-021-00339-6
13. Wang J, Wong YK, and Liao F. What has traditional Chinese medicine delivered for modern medicine? Expert Rev Mol Med. (2018) 20:e4. doi: 10.1017/erm.2018.3
14. Zhang X, Qiu H, Li C, Cai P, and Qi F. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. Biosci Trends. (2021) 15:283–98. doi: 10.5582/bst.2021.01318
15. Chen P, Wu Q, Feng J, Yan L, Sun Y, Liu S, et al. Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis. Signal Transduct Target Ther. (2020) 5:51. doi: 10.1038/s41392-020-0149-3
16. Fu X, He Y, Li M, Huang Z, and Najafi M. Targeting of the tumor microenvironment by curcumin. BioFactors. (2021) 47:914–32. doi: 10.1002/biof.1776
17. Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, and Kato J-YA. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. (2018) 8:2039. doi: 10.1038/s41598-018-20179-6
18. Zoi V, Galani V, Lianos GD, Voulgaris S, Kyritsis AP, and Alexiou GA. The role of curcumin in cancer treatment. Biomedicines. (2021) 9:1086. doi: 10.3390/biomedicines9091086
19. Yu L, Lu M, Jia D, Ma J, Ben-Jacob E, Levine H, et al. Modeling the genetic regulation of cancer metabolism: interplay between glycolysis and oxidative phosphorylation. Cancer Res. (2017) 77:1564–74. doi: 10.1158/0008-5472.CAN-16-2074
20. Liberti MV and Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. (2016) 41:211–8. doi: 10.1016/j.tibs.2015.12.001
21. Schiliro C and Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. (2021) 10:1056. doi: 10.3390/cells10051056
22. Yang J, Ren B, Yang G, Wang H, Chen G, You L, et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell Mol Life Sci. (2020) 77:305–21. doi: 10.1007/s00018-019-03278-z
23. Cui Y, Li C, Sang F, Cao W, Qin Z, and Zhang P. Natural products targeting glycolytic signaling pathways-an updated review on anti-cancer therapy. Front Pharmacol. (2022) 13:1035882. doi: 10.3389/fphar.2022.1035882
24. Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. (2020) 39:126. doi: 10.1186/s13046-020-01629-4
25. Xu S and Herschman HR. A tumor agnostic therapeutic strategy for hexokinase 1–null/hexokinase 2–positive cancers. Cancer Res. (2019) 79:5907–14. doi: 10.1158/0008-5472.CAN-19-1789
26. Siu M, Jiang YX, Wang JJ, Leung T, Han C, Tsang B, et al. Hexokinase 2 regulates ovarian cancer cell migration, invasion and stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 signaling cascades. Cancers (Basel). (2019) 11:813. doi: 10.3390/cancers11060813
27. Guo D, Meng Y, Jiang X, and Lu Z. Hexokinases in cancer and other pathologies. Cell Insight. (2023) 2:100077. doi: 10.1016/j.cellin.2023.100077
28. Kim S, Koh J, Song SG, Yim J, Kim M, Keam B, et al. High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration. BMC Cancer. (2022) 22:1120. doi: 10.1186/s12885-022-10239-6
29. Anderson M, Marayati R, Moffitt R, and Yeh JJ. Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget. (2017) 8:56081–94. doi: 10.18632/oncotarget.9760
30. Fan T, Sun G, Sun X, Zhao L, Zhong R, and Peng Y. Tumor energy metabolism and potential of 3-bromopyruvate as an inhibitor of aerobic glycolysis: implications in tumor treatment. Cancers (Basel). (2019) 11:317. doi: 10.3390/cancers11030317
31. Zhang D, Li J, Wang F, Hu J, Wang S, and Sun Y. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. (2014) 355:176–83. doi: 10.1016/j.canlet.2014.09.003
32. Wang H, Penaloza T, Manea AJ, and Gao X. PFKP: More than phosphofructokinase. Adv Cancer Res. (2023) 160:1–5. doi: 10.1016/bs.acr.2023.03.001
33. Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, et al. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. (2013) 58:182–91. doi: 10.1002/hep.26310
34. Sha X, Wang K, Wang F, Zhang C, Yang L, and Zhu X. Silencing PFKP restrains the stemness of hepatocellular carcinoma cells. Exp Cell Res. (2021) 407:112789. doi: 10.1016/j.yexcr.2021.112789
35. Lee JH, Liu R, Li J, Wang Y, Tan L, Li XJ, et al. EGFR-phosphorylated platelet isoform of phosphofructokinase 1 promotes PI3K activation. Mol Cell. (2018) 70:197–210.e7. doi: 10.1016/j.molcel.2018.03.018
36. Puckett DL, Alquraishi M, Chowanadisai W, and Bettaieb A. The role of PKM2 in metabolic reprogramming: insights into the regulatory roles of non-coding RNAs. Int J Mol Sci. (2021) 22:1171. doi: 10.3390/ijms22031171
37. Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, and Sherwood R. Fecal M2-pyruvate kinase (M2-PK): A novel marker of intestinal inflammation. Inflammation Bowel Dis. (2007) 13:1374–8. doi: 10.1002/ibd.20214
38. Zahra K, Dey T, Ashish, Mishra SP, and Pandey U. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front Oncol. (2020) 10:159. doi: 10.3389/fonc.2020.00159
39. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res. (2012) 72:1438–48. doi: 10.1158/0008-5472.CAN-11-3024
40. Azoitei N, Becher A, Steinestel K, Rouhi A, Diepold K, Genze F, et al. PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation. Mol Cancer. (2016) 15:3. doi: 10.1186/s12943-015-0490-2
41. Claps G, Faouzi S, Quidville V, Chehade F, Shen S, Vagner S, et al. The multiple roles of LDH in cancer. Nat Rev Clin Oncol. (2022) 19:749–62. doi: 10.1038/s41571-022-00686-2
42. Rogatzki MJ, Ferguson BS, Goodwin ML, and Gladden LB. Lactate is always the end product of glycolysis. Front Neurosci. (2015) 9:22. doi: 10.3389/fnins.2015.00022
43. Dhup S, Kumar Dadhich R, Ettore Porporato P, and Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des. (2012) 18:1319–30. doi: 10.2174/138161212799504902
44. Duan Q, Zhang S, Wang Y, Lu D, Sun Y, and Wu Y. Proton-coupled monocarboxylate transporters in cancer: From metabolic crosstalk, immunosuppression and anti-apoptosis to clinical applications. Front Cell Dev Biol. (2022) 10:1069555. doi: 10.3389/fcell.2022.1069555
45. Kong SC, Nøhr-Nielsen A, Zeeberg K, Reshkin SJ, Hoffmann EK, Novak I, et al. Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells. Pancreas. (2016) 45:1036–47. doi: 10.1097/MPA.0000000000000571
46. Beloueche-Babari M, Casals Galobart T, Delgado-Goni T, Wantuch S, Parkes HG, Tandy D, et al. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration. Br J Cancer. (2020) 122:895–903. doi: 10.1038/s41416-019-0717-x
47. Wang J, Ye C, Chen C, Xiong H, Xie B, Zhou J, et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. (2017) 8:16875–86. doi: 10.18632/oncotarget.15171
48. Miller ZA, Muthuswami S, Mueller A, Ma RZ, Sywanycz SM, Naik A, et al. GLUT1 inhibitor BAY-876 induces apoptosis and enhances anti-cancer effects of bitter receptor agonists in head and neck squamous carcinoma cells. Cell Death Discov. (2024) 10:339. doi: 10.1038/s41420-024-02106-z
49. Pavlova NN and Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. (2016) 23:27–47. doi: 10.1016/j.cmet.2015.12.006
50. Chen J, Cui L, Lu S, and Xu S. Amino acid metabolism in tumor biology and therapy. Cell Death Dis. (2024) 15:42. doi: 10.1038/s41419-024-06435-w
51. Do LK, Lee HM, Ha YS, Lee CH, and Kim J. Amino acids in cancer: Understanding metabolic plasticity and divergence for better therapeutic approaches. Cell Rep. (2025) 44:115529. doi: 10.1016/j.celrep.2025.115529
52. Tosta Pérez M, Herrera Belén L, Letelier P, Calle Y, Pessoa A, and Farías JG. l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review. Med Oncol. (2023) 40:150. doi: 10.1007/s12032-023-02014-9
53. Fan Y, Xue H, Li Z, Huo M, Gao H, and Guan X. Exploiting the Achilles’ heel of cancer: disrupting glutamine metabolism for effective cancer treatment. Front Pharmacol. (2024) 15:1345522. doi: 10.3389/fphar.2024.1345522
54. Patel D, Menon D, Bernfeld E, Mroz V, Kalan S, Loayza D, et al. Aspartate rescues S-phase arrest caused by suppression of glutamine utilization in KRas-driven cancer cells. J Biol Chem. (2016) 291:9322–9. doi: 10.1074/jbc.M115.710145
55. Zhao X, Sakamoto S, Saito S, Pae S, Yamada Y, Kanaoka S, et al. The regulation and function of the amino acid transporters LAT1, ASCT2, xCT in urological cancers. Receptors. (2024) 3:474–93. doi: 10.3390/receptors3040024
56. Jin J, Byun JK, Choi YK, and Park KG. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. (2023) 55:706–15. doi: 10.1038/s12276-023-00971-9
57. Huang D, Cai H, and Huang H. Serine metabolism in tumor progression and immunotherapy. Discover Oncol. (2025) 16:628. doi: 10.1007/s12672-025-02358-w
58. Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, et al. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. (2017) 544:372–6. doi: 10.1038/nature22056
59. He L, Long J, Zhou X, Liu Y, Li T, and Wu X. Serine is required for the maintenance of redox balance and proliferation in the intestine under oxidative stress. FASEB J. (2020) 34:4702–17. doi: 10.1096/fj.201902690R
60. Chan B, VanderLaan PA, and Sukhatme VP. 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. Biochem Biophys Res Commun. (2013) 439:247–51. doi: 10.1016/j.bbrc.2013.08.048
61. Butler M, van der Meer LT, and van Leeuwen FN. Amino acid depletion therapies: starving cancer cells to death. Trends Endocrinol Metab. (2021) 32:367–81. doi: 10.1016/j.tem.2021.03.003
62. Ishak Gabra MB, Yang Y, Li H, Senapati P, Hanse EA, Lowman XH, et al. Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. Nat Commun. (2020) 11:3326. doi: 10.1038/s41467-020-17181-w
63. Kanarek N, Keys HR, Cantor JR, Lewis CA, Chan SH, Kunchok T, et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature. (2018) 559:632–6. doi: 10.1038/s41586-018-0316-7
64. Fu Y, Zou T, Shen X, Nelson PJ, Li J, Wu C, et al. Lipid metabolism in cancer progression and therapeutic strategies. MedComm (Beijing). (2021) 2:27–59. doi: 10.1002/mco2.27
65. Jin HR, Wang J, Wang ZJ, Xi MJ, Xia BH, Deng K, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. (2023) 16:103. doi: 10.1186/s13045-023-01498-2
66. Snaebjornsson MT, Janaki-Raman S, and Schulze A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab. (2020) 31:62–76. doi: 10.1016/j.cmet.2019.11.010
67. Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. (2013) 73:2850–62. doi: 10.1158/0008-5472.CAN-13-0382-T
68. Fhu CW and Ali A. Fatty acid synthase: an emerging target in cancer. Molecules. (2020) 25:3935. doi: 10.3390/molecules25173935
69. Ni T, He Z, Dai Y, Yao J, Guo Q, and Wei L. Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1α-modulated fatty acid metabolism. Cell Death Dis. (2017) 8:e2865–5. doi: 10.1038/cddis.2017.261
70. Qu Q, Zeng F, Liu X, Wang QJ, and Deng F. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis. (2016) 7:e2226–6. doi: 10.1038/cddis.2016.132
71. Ma J, Wang S, Zhang P, Zheng S, Li X, Li J, et al. Emerging roles for fatty acid oxidation in cancer. Genes Dis. (2025) 12:101491. doi: 10.1016/j.gendis.2024.101491
72. Guerrero-Rodríguez SL, Mata-Cruz C, Pérez-Tapia SM, and Velasco-Velázquez MA. Role of CD36 in cancer progression, stemness, and targeting. Front Cell Dev Biol. (2022) 10:1079076. doi: 10.3389/fcell.2022.1079076
73. Vecchi L, Araújo TG, Azevedo FVP de V, Mota STS, Ávila V de MR, Ribeiro MA, et al. Phospholipase A2 drives tumorigenesis and cancer aggressiveness through its interaction with annexin A1. Cells. (2021) 10:1472. doi: 10.3390/cells10061472
74. Buhmeida A, Bendardaf R, Hilska M, Laine J, Collan Y, Laato M, et al. PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. Ann Oncol. (2009) 20:1230–5. doi: 10.1093/annonc/mdn783
75. He B, Bie Q, Zhao R, Yan Y, Dong G, Zhang B, et al. Arachidonic acid released by PIK3CA mutant tumor cells triggers Malignant transformation of colonic epithelium by inducing chromatin remodeling. Cell Rep Med. (2024) 5:101510. doi: 10.1016/j.xcrm.2024.101510
76. Cui L, Liu R, Han S, Zhang C, Wang B, Ruan Y, et al. Targeting arachidonic acid metabolism enhances immunotherapy efficacy in ARID1A-deficient colorectal cancer. Cancer Res. (2025) 85:925–41. doi: 10.1158/0008-5472.CAN-24-1611
77. Warda M, Tekin S, Gamal M, Khafaga N, Çelebi F, and Tarantino G. Lipid rafts: novel therapeutic targets for metabolic, neurodegenerative, oncological, and cardiovascular diseases. Lipids Health Dis. (2025) 24:147. doi: 10.1186/s12944-025-02563-0
78. Li HX, Wang SQ, Lian ZX, Deng SL, and Yu K. Relationship between tumor infiltrating immune cells and tumor metastasis and its prognostic value in cancer. Cells. (2022) 12:64. doi: 10.3390/cells12010064
79. Shi R, Tang Y, and Miao H. Metabolism in tumor microenvironment: Implications for cancer immunotherapy. MedComm (Beijing). (2020) 1:47–68. doi: 10.1002/mco2.6
80. Arner EN and Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. (2023) 41:421–33. doi: 10.1016/j.ccell.2023.01.009
81. Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. (2015) 162:1229–41. doi: 10.1016/j.cell.2015.08.016
82. Chen DP, Ning WR, Jiang ZZ, Peng ZP, Zhu LY, Zhuang SM, et al. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. J Hepatol. (2019) 71:333–43. doi: 10.1016/j.jhep.2019.04.007
83. Sun K, Shen Y, Xiao X, Xu H, Zhang Q, and Li M. Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight. Front Oncol. (2024) 14:1506849. doi: 10.3389/fonc.2024.1506849
84. Kumagai S, Koyama S, Itahashi K, Tanegashima T, tzu LY, Togashi Y, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. (2022) 40:201–18.e9. doi: 10.1016/j.ccell.2022.01.001
85. Zhang A, Xu Y, Xu H, Ren J, Meng T, Ni Y, et al. Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17. Theranostics. (2021) 11:3839–52. doi: 10.7150/thno.53749
86. Xu S, Chaudhary O, Rodríguez-Morales P, Sun X, Chen D, Zappasodi R, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity. (2021) 54:1561–77.e7. doi: 10.1016/j.immuni.2021.05.003
87. Karimova AF, Khalitova AR, Suezov R, Markov N, Mukhamedshina Y, Rizvanov AA, et al. Immunometabolism of tumor-associated macrophages: A therapeutic perspective. Eur J Cancer. (2025) 220:115332. doi: 10.1016/j.ejca.2025.115332
88. Sun Z, Zhang L, and Liu L. Reprogramming the lipid metabolism of dendritic cells in tumor immunomodulation and immunotherapy. Biomed Pharmacother. (2023) 167:115574. doi: 10.1016/j.biopha.2023.115574
89. Loftus RM, Assmann N, Kedia-Mehta N, O’Brien KL, Garcia A, Gillespie C, et al. Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. Nat Commun. (2018) 9:2341. doi: 10.1038/s41467-018-04719-2
90. Lin SC and Hardie DG. AMPK: sensing glucose as well as cellular energy status. Cell Metab. (2018) 27:299–313. doi: 10.1016/j.cmet.2017.10.009
91. Perez-Castro L, Garcia R, Venkateswaran N, Barnes S, and Conacci-Sorrell M. Tryptophan and its metabolites in normal physiology and cancer etiology. FEBS J. (2023) 290:7–27. doi: 10.1111/febs.16245
92. Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. (2016) 167:829–42.e13. doi: 10.1016/j.cell.2016.09.031
93. Karadima E, Chavakis T, and Alexaki VI. Arginine metabolism in myeloid cells in health and disease. Semin Immunopathol. (2025) 47:11. doi: 10.1007/s00281-025-01038-9
94. Bhatt K, Orlando T, Meuwis MA, Louis E, Stefanuto PH, and Focant JF. Comprehensive insight into colorectal cancer metabolites and lipids for human serum: A proof-of-concept study. Int J Mol Sci. (2023) 24:9614. doi: 10.3390/ijms24119614
95. Chen F, Fu Y, Bai G, Qiu J, and Hua K. Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming. Front Pharmacol. (2025) 16:1634413. doi: 10.3389/fphar.2025.1634413
96. Artyomov MN and Van den Bossche J. Immunometabolism in the single-cell era. Cell Metab. (2020) 32:710–25. doi: 10.1016/j.cmet.2020.09.013
97. Sun C, Wang A, Zhou Y, Chen P, Wang X, Huang J, et al. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nat Commun. (2023) 14:2692. doi: 10.1038/s41467-023-38360-5
98. Bartusik-Aebisher D, Justin Raj DR, and Aebisher D. Detection of protein and metabolites in cancer analyses by MALDI 2000–2025. Cancers (Basel). (2025) 17:3524. doi: 10.3390/cancers17213524
99. Krestensen KK, Hendriks TFE, Grgic A, Derweduwe M, De Smet F, Heeren RMA, et al. Molecular profiling of glioblastoma patient-derived single cells using combined MALDI-MSI and MALDI-IHC. Anal Chem. (2025) 97:3846–54. doi: 10.1021/acs.analchem.4c03821
100. Ismail NI, Othman I, Abas F, H. Lajis N, and Naidu R. Mechanism of apoptosis induced by curcumin in colorectal cancer. Int J Mol Sci. (2019) 20:2454. doi: 10.3390/ijms20102454
101. Gao F, Li M, Liu WB, Zhou ZS, Zhang R, Li JL, et al. Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2-mediated glycolysis. Oncol Rep. (2015) 33:1533–9. doi: 10.3892/or.2015.3727
102. Yilmaz M, Kantarjian H, and Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. (2021) 11:123. doi: 10.1038/s41408-021-00514-3
103. Lin ST, Tu SH, Yang PS, Hsu SP, Lee WH, Ho CT, et al. Apple Polyphenol Phloretin Inhibits Colorectal Cancer Cell Growth via Inhibition of the Type 2 Glucose Transporter and Activation of p53-Mediated Signaling. J Agric Food Chem. (2016) 64:6826–37. doi: 10.1021/acs.jafc.6b02861
104. Fang J, Bao YY, Zhou SH, and Fan J. Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1. Mol Med Rep. (2015) 12:6461–6. doi: 10.3892/mmr.2015.4233
105. Mardones P, Rubinsztein DC, and Hetz C. Mystery solved: Trehalose kickstarts autophagy by blocking glucose transport. Sci Signal. (2016) 9:fs2. doi: 10.1126/scisignal.aaf1937
106. Tuli HS, Tuorkey MJ, Thakral F, Sak K, Kumar M, Sharma AK, et al. Molecular mechanisms of action of genistein in cancer: recent advances. Front Pharmacol. (2019) 10:1336. doi: 10.3389/fphar.2019.01336
107. Pavese JM, Farmer RL, and Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev. (2010) 29:465–82. doi: 10.1007/s10555-010-9238-z
108. Iqbal MA and Bamezai RNK. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin. PloS One. (2012) 7:e36764. doi: 10.1371/journal.pone.0036764
109. Porporato PE, Dhup S, Dadhich RK, Copetti T, and Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front Pharmacol. (2011) 2:49. doi: 10.3389/fphar.2011.00049
110. Rathod B, Chak S, Patel S, and Shard A. Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents. RSC Med Chem. (2021) 12:1121–41. doi: 10.1039/D1MD00045D
111. Feng Y, Xiong Y, Qiao T, Li X, Jia L, and Han Y. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med. (2018) 7:6124–36. doi: 10.1002/cam4.1820
112. Yu H, Yin Y, Yi Y, Cheng Z, Kuang W, Li R, et al. Targeting lactate dehydrogenase A (LDHA) exerts antileukemic effects on T-cell acute lymphoblastic leukemia. Cancer Commun. (2020) 40:501–17. doi: 10.1002/cac2.12080
113. Feng A, Yang S, Sun Y, Zhang L, Bo F, and Li L. Development and evaluation of oleanolic acid dosage forms and its derivatives. BioMed Res Int. (2020) 2020:1308749. doi: 10.1155/2020/1308749
114. Li Y, Xu Q, Yang W, Wu T, and Lu X. Oleanolic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells. Gene. (2019) 712:143956. doi: 10.1016/j.gene.2019.143956
115. Lim DY, Jeong Y, Tyner AL, and Park JHY. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiology-Gastrointestinal Liver Physiol. (2007) 292:G66–75. doi: 10.1152/ajpgi.00248.2006
116. Kisková T and Kassayová M. Resveratrol action on lipid metabolism in cancer. Int J Mol Sci. (2019) 20:2704. doi: 10.3390/ijms20112704
117. Ramasamy TS, Ayob AZ, Myint HHL, Thiagarajah S, and Amini F. Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy. Cancer Cell Int. (2015) 15:96. doi: 10.1186/s12935-015-0241-x
118. Rauf A, Abu-Izneid T, Khalil AA, Imran M, Shah ZA, Bin ET, et al. Berberine as a potential anticancer agent: A comprehensive review. Molecules. (2021) 26:7368. doi: 10.3390/molecules26237368
119. Chen X, Zou D, Chen X, Wu H, and Xu D. Hesperetin inhibits foam cell formation and promotes cholesterol efflux in THP-1-derived macrophages by activating LXRα signal in an AMPK-dependent manner. J Physiol Biochem. (2021) 77:405–17. doi: 10.1007/s13105-020-00783-9
120. Wang D, Zhu L, Liu H, Feng X, Zhang C, Li T, et al. Huangqin tang alleviates colitis-associated colorectal cancer via amino acids homeostasisand PI3K/AKT/mtor pathway modulation. J Ethnopharmacol. (2024) 334:118597. doi: 10.1016/j.jep.2024.118597
121. Lu Z-H, Ding Y, Wang Y-J, Chen C, Yao X-R, Yuan X-M, et al. Early administration of Wumei Wan inhibit myeloid-derived suppressor cells via PI3K/Akt pathway and amino acids metabolism to prevent colitis-associated colorectal cancer. J Ethnopharmacol. (2024) 333:118260. doi: 10.1016/j.jep.2024.118260
122. Zhu S, Wei L, Lin G, Tong Y, Zhang J, Jiang X, et al. Metabolic alterations induced by Kudingcha lead to cancer cell apoptosis and metastasis inhibition. Nutr Cancer. (2020) 72:696–707. doi: 10.1080/01635581.2019.1645865
123. Zheng C, Han L, and Wu S. A metabolic investigation of anticancer effect of G. glabra root extract on nasopharyngeal carcinoma cell line, C666-1. Mol Biol Rep. (2019) 46:3857–64. doi: 10.1007/s11033-019-04828-1
124. Nie S, Zhao Y, Qiu X, Wang W, Yao Y, Yi M, et al. Metabolomic study on nude mice models of gastric cancer treated with modified Si Jun Zi Tang via HILIC UHPLC-Q-TOF/MS analysis. Evidence-Based Complementary Altern Med. (2019) 2019:1–18. doi: 10.1155/2019/3817879
125. Cheng X, Wang Y, Johnson B, and You M. Mitochondria-targeted strategies in tumor immunity. Front Immunol. (2025) 16:1646138. doi: 10.3389/fimmu.2025.1646138
126. Zhang Z, Tang S, Qi M, Zhao H, Wu M, and Huang SW. Mitochondria-targeting natural product rhein conjugated with dichloroacetate as the dual inhibitor of glycolysis and oxidative phosphorylation to off energize cancer cells and induce ROS storm. Theranostics. (2025) 15:4909–29. doi: 10.7150/thno.107812
127. Al Shemaili J, Mensah-Brown E, Parekh K, Thomas SA, Attoub S, Hellman B, et al. Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer. Eur J Cancer. (2014) 50:1391–8. doi: 10.1016/j.ejca.2014.01.002
128. Oh JM, Kim E, and Chun S. Ginsenoside compound K induces ros-mediated apoptosis and autophagic inhibition in human neuroblastoma cells in vitro and in vivo. Int J Mol Sci. (2019) 20:4279. doi: 10.3390/ijms20174279
129. Saunier E, Antonio S, Regazzetti A, Auzeil N, Laprévote O, Shay JW, et al. Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells. Sci Rep. (2017) 7:6945. doi: 10.1038/s41598-017-07006-0
130. Nakaya M, Xiao Y, Zhou X, Chang JH, Chang M, Cheng X, et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity. (2014) 40:692–705. doi: 10.1016/j.immuni.2014.04.007
131. Craveiro M, Cretenet G, Mongellaz C, Matias MI, Caron O, de Lima MCP, et al. Resveratrol stimulates the metabolic reprogramming of human CD4 + T cells to enhance effector function. Sci Signal. (2017) 10:eaal3024. doi: 10.1126/scisignal.aal3024
132. Carrasco-Pozo C, Tan KN, and Avery VM. Hemin prevents increased glycolysis in macrophages upon activation: protection by microbiota-derived metabolites of polyphenols. Antioxidants. (2020) 9:1109. doi: 10.3390/antiox9111109
133. Ma JL, Yang PY, Rui YC, Lu L, Kang H, and Zhang J. Hemin modulates cytokine expressions in macrophage-derived foam cells via heme oxygenase-1 induction. J Pharmacol Sci. (2007) 103:261–6. doi: 10.1254/jphs.FP0060270
134. Wu MM, Wang QM, Huang BY, Mai CT, Wang CL, Wang TT, et al. Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. Pharmacol Res. (2021) 172:105796. doi: 10.1016/j.phrs.2021.105796
135. Noy R and Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. (2014) 41:49–61. doi: 10.1016/j.immuni.2014.06.010
136. Poltavets V, Kochetkova M, Pitson SM, and Samuel MS. The role of the extracellular matrix and its molecular and cellular regulators in cancer cell plasticity. Front Oncol. (2018) 8:431. doi: 10.3389/fonc.2018.00431
137. Dong S, Guo X, Han F, He Z, and Wang Y. Emerging role of natural products in cancer immunotherapy. Acta Pharm Sin B. (2022) 12:1163–85. doi: 10.1016/j.apsb.2021.08.020
138. Kroemer G, Galluzzi L, Kepp O, and Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. (2013) 31:51–72. doi: 10.1146/annurev-immunol-032712-100008
139. Granato M, Gilardini Montani MS, Filardi M, Faggioni A, and Cirone M. Capsaicin triggers immunogenic PEL cell death, stimulates DCs and reverts PEL-induced immune suppression. Oncotarget. (2015) 6:29543–54. doi: 10.18632/oncotarget.4911
140. Son K-J, Choi K-R, Lee SJ, and Lee H. Immunogenic cell death induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy. Immune Netw. (2016) 16:75. doi: 10.4110/in.2016.16.1.75
141. Zhang Y, Yang S, Yang Y, and Liu T. Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells. Infect Agent Cancer. (2019) 14:27. doi: 10.1186/s13027-019-0247-4
142. Zhang J, Shen L, Li X, Song W, Liu Y, and Huang L. Nanoformulated codelivery of quercetin and alantolactone promotes an antitumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer. ACS Nano. (2019) 13:12511–24. doi: 10.1021/acsnano.9b02875
143. Chen HM, Wang PH, Chen SS, Wen CC, Chen YH, Yang WC, et al. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunology Immunother. (2012) 61:1989–2002. doi: 10.1007/s00262-012-1258-9
144. Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X, et al. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Int Immunopharmacol. (2019) 75:105824. doi: 10.1016/j.intimp.2019.105824
145. Cuyàs E, Pérez-Sánchez A, Micol V, Menendez JA, and Bosch-Barrera J. STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK -rearranged lung cancer. Cell Cycle. (2016) 15:3413–8. doi: 10.1080/15384101.2016.1245249
146. Wang Z, Li MY, Zhang ZH, Zuo HX, Wang JY, Xing Y, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells. Pharmacol Res. (2020) 155:104727. doi: 10.1016/j.phrs.2020.104727
147. Xu R, Wu J, Zhang X, Zou X, Li C, Wang H, et al. Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1/PD- L1-dependent T cell immunization. Pharmacol Res. (2020) 152:104623. doi: 10.1016/j.phrs.2019.104623
148. Liu W, Fan T, Li M, Zhang G, Guo W, Yang X, et al. Andrographolide potentiates PD-1 blockade immunotherapy by inhibiting COX2-mediated PGE2 release. Int Immunopharmacol. (2020) 81:106206. doi: 10.1016/j.intimp.2020.106206
149. Dong M, Meng Z, Kuerban K, Qi F, Liu J, Wei Y, et al. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. Cell Death Dis. (2018) 9:1039. doi: 10.1038/s41419-018-1099-3
150. Xu H, Hu M, Liu M, An S, Guan K, Wang M, et al. Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model. Biomaterials. (2020) 235:119769. doi: 10.1016/j.biomaterials.2020.119769
151. Ajazuddin SS. Applications of novel drug delivery system for herbal formulations. Fitoterapia. (2010) 81:680–9. doi: 10.1016/j.fitote.2010.05.001
152. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres M del P, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. (2018) 16:71. doi: 10.1186/s12951-018-0392-8
153. Zhang L, Lin Z, Chen Y, Gao D, Wang P, Lin Y, et al. Co-delivery of Docetaxel and Resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer. Eur J Pharm Sci. (2022) 174:106199. doi: 10.1016/j.ejps.2022.106199
154. Chen Y, Lu Y, Lee RJ, and Xiang G. Nano encapsulated curcumin: and its potential for biomedical applications. Int J Nanomed. (2020) 15:3099–120. doi: 10.2147/IJN.S210320
Keywords: cancer immunotherapy, immune metabolism regulation, metabolic reprogramming, natural products, tumor microenvironment
Citation: Fan X, Guo S, Li W, Wang Y, Bao J, He J and Jin H (2026) Natural products as metabolic modulators to enhance cancer immunotherapy: reprogramming the tumor microenvironment. Front. Immunol. 16:1740644. doi: 10.3389/fimmu.2025.1740644
Received: 06 November 2025; Accepted: 29 December 2025; Revised: 29 December 2025;
Published: 14 January 2026.
Edited by:
Zong Sheng Guo, University at Buffalo, United StatesReviewed by:
Chi-Heng Wu, Dren Bio, Inc., United StatesXingxing Yuan, Heilongjiang University of Chinese Medicine, China
Copyright © 2026 Fan, Guo, Li, Wang, Bao, He and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hongtao Jin, amluaG9uZ3Rhb0BpbW0uYWMuY24=; Jiuming He, aGVqaXVtaW5nQGltbS5hYy5jbg==